Case Report

A Case Report of Premalignant Plasma Cell Dyscrasia-Induced Renal Failure in a 31-Year-Old Female

Ayrton Bangolo,1 Mahabuba Akhter,1 Amer Jarri,1 Manpreet Kaur,1 Ali Atoot,2 Parul Jandir,1 Mahmood Ibrahim,1 Lochana Manandhar,3 and Adam Atoot1

1Hackensack, Meridian Health Palisades Medical Center, Department of Internal Medicine, North Bergen, NJ, USA
2Hackensack University Medical Center, Department of Anesthesia, Hackensack, NJ, USA
3Hackensack Meridian Health Palisades Medical Center, Department of Nephrology, North Bergen, NJ, USA

Correspondence should be addressed to Ayrton Bangolo; ayrtonbangolo@yahoo.com

Received 16 December 2021; Accepted 24 May 2022; Published 7 June 2022

Academic Editor: Kostas Konstantopoulos

Copyright © 2022 Ayrton Bangolo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Monoclonal gammopathy of renal significance (MGRS) is a rare disorder in which monoclonal immunoglobulin secreted by nonmalignant B cell or plasma cell clone causes kidney damage. Although MGRS is a premalignant condition, it can cause severe kidney disease and end-stage renal disease (ESRD) at any age. Herein, we present a 31-year-old female with past medical history of lupus nephritis who presented with signs of volume overload and worsening renal function despite adequate immunosuppressive therapy. Renal biopsy revealed heavy and light chain deposition consistent with MGRS. This case report demonstrates the importance of including MGRS in the differential diagnosis of worsening renal function despite adequate treatment, raising awareness of this premalignant yet morbid condition.

1. Introduction

Monoclonal gammopathy of undetermined significance (MGUS) consists of a premalignant clonal plasma cell or lymphoplasmacytic proliferative disorder. MGUS is characterized by the absence of end organ damage [1]. However, some patients, meeting diagnosis criteria of MGUS can develop significant kidney injury, and the condition is then termed monoclonal gammopathy of renal significance (MGRS) [2]. MGRS is associated with high morbidity due to the severity of renal lesions. Suppression of monoclonal immunoglobulins (MIg) often improves outcome [3]. Here, we report the case of a 31-year-old female with stage 4 lupus nephritis and worsening renal function despite adequate treatment, found to have MIg on renal biopsy. With this case report we aim to encourage physicians to include MGRS in the differential diagnosis of rapidly progressing renal failure, as early detection and intervention will improve the outcome.

2. Case Presentation

This is a 31-year-old female with past medical history significant for stage IV lupus nephritis who presented for evaluation of a 2-day history of worsening face and extremities swelling. The patient denied any recent insect bite, joint pain, hematuria, or recent upper respiratory tract infection. Of note, the patient was evaluated a year ago for the same symptoms and was found to have severe renal dysfunction. A renal biopsy at that time revealed stage IV lupus nephritis. The patient was discharged on prednisone and mycophenolate. However, she reports noncompliance to the regimen.

Physical exam was notable for facial swelling, bilateral jugular venous distention, and 3+ bilateral lower extremity edema. Laboratory results revealed a creatinine of 7.58 (0.6–1.2) milligram per deciliter (mg/dL), Creatinine a year ago upon discharge was 1.21 mg/dL. She was also found to be hyponatremic, with low serum protein, elevated serum free
kappa and lambda light chains, and normal kappa/lambda ratio as seen in Table 1.

The patient was started back on prednisone and mycophenolate which she had self-discontinued; nephrology was consulted as well. The patient’s creatinine further deteriorated despite being on the regimen. A serum electrophoresis revealed a visible faint band with polyclonal pattern in the gamma region, a developing plasma cell disorder could not be excluded as seen in Table 2. A subsequent serum immunofixation revealed a faint band in immunoglobulin G (IgG) and lambda against a dense polyclonal background.

The patient was continued on prednisone and mycophenolate, and furosemide was added to the regimen with some improvement of the volume overload. She underwent a renal biopsy which revealed diffuse proliferative

---

**Table 1: Laboratory values on admission and a year ago.**

| Laboratory values                                      | Values               |
|--------------------------------------------------------|----------------------|
| Creatinine upon admission                              | 7.58 (0.6–1.2) mg/dL |
| Creatinine a year ago upon discharge                    | 1.21 mg/dL           |
| Blood urea nitrogen                                     | 38 (7–25) mg/dL      |
| Total serum protein                                     | 4.5 (6.4–8.9) g/dL   |
| Serum albumin                                           | 2.2 (3.5–5.7) g/dL   |
| Sodium                                                 | 6.8 (8.6–10.3) mg/dL |
| Calcium                                                 | 129 (136–145) mmol/L |
| 24-hours total urine protein                            | 6456 mg/24 hours (<150 mg/24 hours) |
| Serum complement 3                                      | 56 (83–193) mg/dL    |
| Serum complement 4                                      | 24 (15–57) mg/dL     |
| Free kappa light chain in the serum                     | 44.9 (3.3–19.4) mg/L |
| Free lambda light chain in the serum                    | 47.1 (5.7–26.3) mg/L |
| Kappa/lambda light chain free ratio                     | 0.95 (0.26–1.65)     |
| Antinuclear antibody                                    | Negative             |
| Double-stranded DNA antibody                            | Negative             |

**Table 2: Serum protein electrophoresis with immunofixation.**

| Laboratory values                                      | Values               |
|--------------------------------------------------------|----------------------|
| Total protein                                           | 3.9 (6.1–8.1) g/dL   |
| Albumin                                                 | 2 (3.8–4.8)          |
| Alpha 1 globulin                                        | 0.3 (0.2–0.3)        |
| Alpha 2 globulin                                        | 0.8 (0.5–0.9)        |
| Beta 1 globulin                                         | 0.3 (0.4–0.6)        |
| Beta 2 globulin                                         | 0.2 (0.2–0.5)        |
| Gamma globulin                                          | 0.4 (0.8–1.7)        |
| Abnormal protein band                                   | Faint band visible with overall polyclonal pattern in the gamma region, a developing plasma cell disorder cannot be excluded |
| Serum immunofixation                                    | A faint band in immunoglobulin G and lambda against a dense polyclonal background. a developing plasma cell disorder cannot be excluded |

---

**Figure 1:** Image (a) showing diffuse proliferative glomerulonephritis, reduced bowman space (green arrow) and increased cellularity in glomeruli (orange arrow). Image (b) showing global glomerular basement membrane duplication (yellow arrow). Image (c) showing cortical scarring (blue arrow).
glomerulonephritis with prominent membranoproliferative features as seen on Figure 1. Immunofluorescence revealed granular, global mesangial, and capillary wall deposits each staining 3+ for IgG-3, complement 3, complement 1, and lambda as seen on Figure 2. Findings were consistent with proliferative glomerulonephritis with monoclonal IgG deposits, and a diagnosis of monoclonal gammopathy of renal significance was then made. The patient was started on bortezomib, cyclophosphamide, and prednisone was switched to dexamethasone, and mycophenolate was discontinued.

3. Discussion

Monoclonal gammopathy of renal significance (MGRS) encompasses patients who would otherwise meet the criteria for monoclonal gammopathy of undetermined significance (MGUS) but demonstrate kidney injury attributable to the underlying monoclonal protein [2]. Monoclonal gammopathy is more frequent in systemic lupus erythematosus (SLE) patients than in the general population [4]. SLE may present with nephritis as the sole disease manifestation [5]. In one study by Giavinti et al. in which nephritis was the initial manifestation of SLE, antinuclear (ANA) and anti-double-stranded DNA antibodies were positive up to 10 years after the original presentation [6]. Our patient was diagnosed, a year ago, with lupus nephritis. However, she did not have any clinical manifestations of SLE, and the ANA and anti-double-stranded DNA antibodies were negative. Given her history of lupus nephritis, the patient was at higher risk of developing MGRS.

In monoclonal gammopathy of renal significance (MGRS), the kidney lesions are primarily caused by the abnormal deposition or activity of monoclonal proteins in the kidney [7]. Monoclonal proteins can also act as autoantibodies directed against complement components, leading to uncontrolled activation of the alternative complement pathway, and causing complement 3 (C3) glomerulopathy [8]. Cases of monoclonal anti-glomerular basement membrane (GBM) disease due to circulating monoclonal antibodies have been reported [9, 10]. Monoclonal deposits must be restricted to a single class of light and/or heavy chain based on immunofluorescence to make the diagnosis of MGRS [11]. For unclear reasons, most patients with proliferative glomerulonephritis with monoclonal immunoglobulin deposits (PGNMID) do not have detectable circulating monoclonal gammopathy by serum and urine monoclonal protein testing [12]. Our patient's renal biopsy revealed monoclonal deposits of a single class of light chain (lambda) and a single class of heavy chain (immunoglobulin G) consistent with MGRS. The biopsy also revealed C3 deposit, consistent with C3 glomerulopathy, and a duplication of GBM was also reported. The patient's biopsy was consistent with proliferative glomerulonephritis with prominent membranoproliferative features and the serum electrophoresis did not reveal a monoclonal spike, and the immunofixation only revealed a faint immunoglobulin G and lambda. These findings are adequate with the literature.

Patients with monoclonal gammopathy-associated proliferative glomerulonephritis (PGNMID or C3 glomerulopathy with monoclonal gammopathy) are at risk for progressive kidney disease and should be treated to prevent further kidney injury and deterioration of kidney function. The treatment focuses upon eradication of the pathologic clone [13]. In patients with a detectable plasma cell clone, a treatment regimen similar to that used to treat multiple myeloma (MM) is recommended [13]. Treatment should be continued for up to six months if there is evidence of a hematologic response and no toxicity [13]. Our patient's biopsy expressed plasma cell monoclonal protein, with a heavy chain (immunoglobulin G) complexed with a light chain (lambda). She qualified for a treatment regimen similar to that used in MM. The patient will be reevaluated for response to treatment at regular intervals.

4. Conclusion

Monoclonal gammopathy of renal significance (MGRS) is a premalignant clonal plasma cell or lymphoplasmacytic proliferative disorder. Although MGRS is a premalignant
condition, it is associated with high morbidity due to the rapidly progressive nature of kidney disease. Early detection is essential, as suppression of immunoglobulin improves the outcome. With this case report, we hope to encourage clinicians to include MGRS in the differential diagnosis of unexplained worsening kidney function and raise awareness of this premalignant yet morbid condition.

Data Availability
All the data generated or analyzed during this study are available from the corresponding author upon request.

Ethical Approval
This study protocol was reviewed and the need for approval was waived by the Ethics Committee at Palisades Medical Center Hackensack Meridian Health.

Consent
Written informed consent was obtained from the patient for publication of this case report and any accompanying images.

Conflicts of Interest
The authors declare that they have no conflicts of interests.

Authors’ Contributions
Ayrton Bangolo searched the literature, wrote, and revised the manuscript. Mahabuba Akhter, Amer Jarri, Manpreet Kaur, Parul Jandir, Ali Atoot, and Mahmood Ibrahim revised and edited the manuscript. Adam Atoot and Lochna Manandhar revised and approved the final version and are the article’s guarantors. All authors certify that they contributed sufficiently to the intellectual content and data analysis. Each author has reviewed the final version of the manuscript and approves it for publication.

References
[1] S. V. Rajkumar, M. A. Dimopoulos, A. Palumbo et al., “International Myeloma working group updated criteria for the diagnosis of multiple myeloma,” The Lancet Oncology, vol. 15, no. 12, pp. e538–e548, 2014.
[2] N. Leung, F. Bridoux, C. A. Hutchison et al., “Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant,” Blood, vol. 120, no. 22, pp. 4292–4295, 2012.
[3] F. Bridoux, N. Leung, N. Leung et al., “Diagnosis of monoclonal gammopathy of renal significance,” Kidney International, vol. 87, no. 4, pp. 698–711, 2015.
[4] Y. M. Ali, M. B. Urowitz, D. Ibanez, and D. D. Gladman, “Monoclonal gammopathy in systemic lupus erythematosus,” Lupus, vol. 16, no. 6, pp. 426–429, 2007.
[5] D. Adu, D. G. Williams, D. Taube et al., “Late onset systemic lupus erythematosus and lupus-like disease in patients with apparent idiopathic glomerulonephritis,” Quarterly Journal of Medicine, vol. 52, no. 208, pp. 471–487, 1983.
[6] A. Gianviti, P. Barsotti, V. Barbera, T. Faraggiana, and G. Rizzoni, “Delayed onset of systemic lupus erythematosus in patients with “full-house” nephropathy,” Pediatric Nephrology, vol. 13, no. 8, pp. 683–687, 1999.
[7] R. H. Sayed, A. D. Wechalekar, J. A. Gilbertson et al., “Natural history and outcome of light chain deposition disease,” Blood, vol. 126, no. 26, pp. 2805–2810, 2015.
[8] S. Meri, V. Koistinen, A. Miettinen, T. Törnroth, and I. J. Seppälä, “Activation of the alternative pathway of complement by monoclonal lambda light chains in membranoproliferative glomerulonephritis,” Journal of Experimental Medicine, vol. 175, no. 4, pp. 939–950, 1992.
[9] M. Turner, A. Crawford, C. Winterbottom et al., “Heavy chain deposition disease presenting with raised anti-GBM antibody levels; a case report,” BMC Nephrology, vol. 21, no. 1, 2020.
[10] S. M. Coley, S. Shirazian, J. Radhakrishnan, and V. D. D’Agati, “Monoclonal IgG1 anti-glomerular basement membrane disease: a case report,” American Journal of Kidney Diseases, vol. 65, no. 2, pp. 322–326, 2015.
[11] N. Klomjit, N. Leung, F. Fervenza, S. Sethi, and L. Zand, “Rate and predictors of finding monoclonal gammopathy of renal significance (MGRS) lesions on kidney biopsy in patients with monoclonal gammopathy,” Journal of the American Society of Nephrology, vol. 31, no. 10, pp. 2400–2411, 2020.
[12] R. Fish, J. Pinney, P. Jain et al., “The incidence of major hemorrhagic complications after renal biopsies in patients with monoclonal gammapathies,” Clinical Journal of the American Society of Nephrology, vol. 5, no. 11, pp. 1977–1980, 2010.
[13] S. Sethi and S. V. Rajkumar, “Monoclonal gammopathy-associated proliferative glomerulonephritis,” Mayo Clinic Proceedings, vol. 88, no. 11, pp. 1284–1293, 2013.